Dimension Therapeutics appoints George Migausky to the Board of Directors

– USA, MA – Dimension Therapeutics, Inc. a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the election of George Migausky to the Company’s Board of Directors. Mr. Migausky brings more than 30 years of senior financial management experience with high-growth life science and technology companies. His election to Dimension’s Board is effective immediately, and he will chair the newly established audit committee.

“We are pleased to welcome George Migausky to Dimension’s Board. George joins at an important time for Dimension, as we have recently achieved a number of key milestones, including our series B financing, and are seeking to accomplish additional near-term goals, including the initiation of our first clinical trial in the second half of this year,” said Annalisa Jenkins, MBBS, MRCP, Dimension’s Chief Executive Officer. “We look forward to benefiting from George’s extensive expertise in growing both private and public companies in the life sciences industry.”

“George has pursued a distinguished career in finance and is a well-regarded leader within the life sciences and orphan disease communities,” stated Ben Auspitz, Partner, Fidelity Biosciences, and Chairman of Dimension’s Board. “We believe his insights will be critical to Dimension and its continuing evolution as a leading rare disease company focused on liver-directed gene therapy.”

Mr. Migausky is Executive Vice President and Chief Financial Officer of Dyax Corp., a biopharmaceutical company advancing biotherapeutics for orphan diseases. Prior to joining Dyax, Mr. Migausky served as the CFO of Wellstat Management Company, a privately held company responsible for managing an affiliated group of six life science and technology companies. Previously, he held CFO positions at several public and private companies, including IGEN International, BioVeris Corporation, Hyperion Catalysis International, and ElectroScan Corporation. At IGEN, Mr. Migausky was instrumental in preparing the company for its initial public offering in 1994, its merger with F. Hoffman La Roche in 2004, and the simultaneous spinoff of BioVeris Corporation as an independent public company. In his senior manager functions, Mr. Migausky has been responsible for Sarbanes-Oxley compliance, public and private equity financings, and corporate partnering arrangements. Mr. Migausky received an M.B.A. from Babson College and a B.S. from Boston College.

Mr. Migausky commented, “I look forward to working with the highly accomplished leadership team at Dimension and to contributing to the Company’s progress innovating novel therapies with the potential to transform the lives of patients with severe, rare genetic diseases.”

About Dimension Therapeutics

Dimension Therapeutics, Inc. is a leading rare disease company focused on developing novel treatments for devastating disorders associated with the liver and based on an industry-leading, extensively validated adeno-associated virus (AAV) platform. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple best-in-class AAV vectors from REGENXBIO, which founded Dimension with Fidelity Biosciences in October 2013. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>